Table 3.

Management of DOAC in atrial fibrillation (AF) and venous thromboembolism patients.

	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
AF dosage	150 mg twice daily	20 mg once daily	5 mg twice daily	60 mg once daily
Criteria for adjustment	CrCL 30–50 mL/min No recommendation: CrCL < 30 mL/min or HD	CrCL 15–50 mL/min No recommendation: CrCL < 15 mL/min or HD	2 of 3 required: body weight ≤ 60 kg age ≥ 80 years SCr ≥ 1.5 mg/dL	CrCL 15–50 mL/min Avoid use if: CrCL < 15 mL/min CrCL > 95 mL/min No recommendation for HD
Dose adjustment	110 mg twice daily	15 mg once daily	2.5 mg twice daily	30 mg once daily
VTE treatment Recurrent VTE VTE prophylaxis	150 mg twice daily 150 mg twice daily 150 mg twice daily	15 mg (21 days) then 20 mg once daily 10 or 20 mg once daily 10 mg once daily	10 mg (7 days) then 5 mg twice daily 2.5 mg twice daily 2.5 mg twice daily	60 mg once daily
Criteria for adjustment	CrCL 30–50 mL/min No recommendation: CrCL < 30 mL/min	Avoid use if: CrCL < 30 mL/min or HD	No recommendation: CrCL < 25 mL/min	CrCL: 15–50 mL/min or body weight ≤ 60 kg Avoid use if: CrCL < 15 mL/min
Dose adjustment	110 mg twice daily			30 mg once daily

AF: atrial fibrillation; VTE: venous thromboembolism; CrCL: creatinine clearance; HD: hemodialysis; SCr: serum creatinine.